Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial — Norberto Perico (2019) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
Shared by
Giuseppe Remuzzi
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
Article
2019
en
Authors
+19 more
NP
Norberto Perico
PR
Piero Ruggenenti
AP
Annalisa Perna
Abstract
1 min read
ClinicalTrials.gov NCT01377246; EudraCT: 2011-000138-12.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2022
Octreotide Lar in Patients with Autosomal Dominant Polycystic Kidney Disease: From Bench to A Novel Perspective of Therapy
Piero Ruggenenti
,
Annalisa Perna
,
Anna Caroli
,
Norberto Perico
,
Mattias Trillini
,
Antonio Pisani
,
Letìzia Spinelli
,
Giuseppe Remuzzi
Article
2013
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial
Anna Caroli
,
Norberto Perico
,
Annalisa Perna
,
Luca Antiga
,
Paolo Brambilla
,
Antonio Pisani
,
Bianca Visciano
,
Massimo Imbriaco
,
Piergiorgio Messa
,
Roberta Cerutti
,
Mauro Dugo
,
Luca Cancian
,
Erasmo Buongiorno
,
Antonio De Pascalis
,
Flavio Gaspari
,
Fabiola Carrara
,
Nadia Rubis
,
Silvia Prandini
,
Andrea Remuzzi
,
Giuseppe Remuzzi
,
Piero Ruggenenti
Article
2023
Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial
Matias Trillini
,
Anna Caroli
,
Norberto Perico
,
Andrea Remuzzi
,
Paolo Brambilla
,
Giulia Villa
,
Annalisa Perna
,
Tobia Peracchi
,
Nadia Rubis
,
Davide Martinetti
,
Rosa Caruso
,
Valentina Fanny Leone
,
Daniela Cugini
,
Fabiola Carrara
,
Giuseppe Remuzzi
,
Piero Ruggenenti
Article
2021
Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial
Piero Ruggenenti
,
Paolo Cravedi
,
Eliana Gotti
,
Annarita Plati
,
Maddalena Marasà
,
Silvio Sandrini
,
Nicola Bossini
,
Franco Citterio
,
Enrico Minetti
,
Domenico Montanaro
,
Ettore Sabadini
,
Regina Tardanico
,
Davide Martinetti
,
Flavio Gaspari
,
Alessandro Villa
,
Annalisa Perna
,
Francesco Peraro
,
Giuseppe Remuzzi
Article
2020
Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial
Emanuele Bosi
,
Carlo Bosi
,
Patrizia Rovere‐Querini
,
Nicasio Mancini
,
Giliola Calori
,
Annalisa Ruggeri
,
Cecilia Canzonieri
,
Luciano Callegaro
,
Massimo Clementi
,
Francesco De Cobelli
,
Massimo Filippi
,
Marco Bregni
Discussion(0)
No comments yet. Be the first to comment.